Use access key #2 to skip to page content.
$16.76 0.70 (4.36%)
7/3/2008 1:00 PM

Omrix Biopharmaceuticals, Inc. (OMRI)

CAPS Rating:
****

A commercial-stage biopharmaceutical company that develops and markets innovative biological products.

View All Commentary (OMRI)

Recs

1

Avatar tiobueno (29.02) Submitted: 4/04/08 12:25 PM : Outperform Start Price: $15.72 OMRI Score: 14.69

March 20, 2008 4:57 PM EDT

Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) CEO, Robert Taub, bought 80,000 shares from 03/19-03/20 at prices from $12.10-$12.31, bringing his stake to 2,797,103 shares.

Shares of Omrix Biopharmaceuticals are trading near 52-week lows and is down 65% year to date.

Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops and markets biosurgical and immunotherapy products derived from human plasma.

Report this Post Replies: 0 | Reply

Featured Broker Partners